The basic research for elucidation of molecular mechanism of the prostate cancer recurrence and the treatment strategy construction
Project/Area Number |
20390421
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Kanazawa University |
Principal Investigator |
NAMIKI Mikio Kanazawa University, 医学系, 教授 (70155985)
|
Co-Investigator(Kenkyū-buntansha) |
MIZOKAMI Atsushi 金沢大学, 附属病院, 講師 (50248580)
KYO Satoru 金沢大学, 医学系, 講師 (50272969)
HIGASHI Tatuya 静岡県立大学, 薬学部, 准教授 (90272963)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2008: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
|
Keywords | 前立腺癌 / DHEA / 間質細胞 / トラニラスト / CTEN / パクリタキセル耐性 / 再燃 / アンドロゲン / 再燃前立腺癌 / TGFβ |
Research Abstract |
1. Adrenal androgen, DHEA, is important for recurrence of prostate cancer. Prostate cancer stromal cells and prostate cancer cells coordinately activate the androgen receptor through synthesis of T and DHT from DHEA. 2. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses TGF-β-associated osteoblastic changes. 3. We identified CTEN, one of important genes that is associated with paclitaxel resistance. Expression of CTEN recovered paclitacel-resistance.
|
Report
(4 results)
Research Products
(14 results)